Practical impact of unannounced audits for combination product makers in the EU
This article was originally published in SRA
Executive Summary
While there is much speculation as to how the new EU regulatory structure for high-risk devices, including device/drug combinations, will pan out, and how soon the new Medical Device Regulation will take effect, there is a more urgent matter for companies to attend: the tighter regulatory environment that will result from the new European Commission documents on the designation and oversight of notified bodies, and on audits by notified bodies1,2.
You may also be interested in...
EU Regulatory Roundup, March 2024: Busy Agenda In Broad Range Of Key Areas
March was an important month for EU medtech regulation with an interesting spread of news relating to the Medical Device and IVD Regulations, the Batteries Regulation, the Artificial Intelligence Act and more.
EU’s Revised Phthalates Guideline Features New Annexes Focused On Alternatives
The effects of phthalates, plasticizers used in many medical devices, on the human endocrine system, have long been debated. But how safe are the alternatives? Updated guidelines give more insight.
Non-Medical Brain Stimulation Devices: Could They Be Down-Classified Again In the EU?
Six types of products that do not have an intended medical purpose fall under the scope of the Medical Device Regulation. Understanding their risks is complex and subject to regular re-examination by the European Commission.